TY - JOUR
T1 - Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease
T2 - A Post Hoc Analysis From the HALT-PKD Trials
AU - HALT-PKD Trial Investigators
AU - Brosnahan, Godela M.
AU - Abebe, Kaleab Z.
AU - Moore, Charity G.
AU - Rahbari-Oskoui, Frederic F.
AU - Bae, Kyongtae T.
AU - Grantham, Jared J.
AU - Schrier, Robert W.
AU - Braun, William E.
AU - Chapman, Arlene B.
AU - Flessner, Michael F.
AU - Harris, Peter C.
AU - Hogan, Marie C.
AU - Perrone, Ronald D.
AU - Miskulin, Dana C.
AU - Steinman, Theodore I.
AU - Torres, Vicente E.
AU - Steinman, Theodore
AU - Wei, Jesse
AU - Czarnecki, Peter
AU - Pedrosa, Ivan
AU - Braun, William
AU - Nurko, Saul
AU - Remer, Erick
AU - Chapman, Arlene
AU - Martin, Diego
AU - Rahbari-Oskoui, Frederic
AU - Mittal, Pardeep
AU - Torres, Vicente
AU - El-Zoghby, Ziad
AU - Glockner, James
AU - King, Bernard
AU - Perrone, Ronald
AU - Halin, Neil
AU - Miskulin, Dana
AU - Schrier, Robert
AU - Brosnahan, Godela
AU - Gitomer, Berenice
AU - Kelleher, Cass
AU - Masoumi, Amirali
AU - Patel, Nayana
AU - Winklhofer, Franz
AU - Grantham, Jared
AU - Yu, Alan
AU - Wang, Connie
AU - Wetzel, Louis
AU - Moore, Charity G.
AU - Bost, James E.
AU - Bae, Kyongtae
AU - Abebe, Kaleab Z.
AU - Miller, J. Philip
N1 - Publisher Copyright:
© 2017 National Kidney Foundation, Inc.
PY - 2018/5
Y1 - 2018/5
N2 - Background: Previous clinical studies of autosomal dominant polycystic kidney disease (ADPKD) reported that loss of kidney function usually follows a steep and relentless course. A detailed examination of individual patterns of decline in estimated glomerular filtration rate (eGFR) has not been performed. Study Design: Longitudinal post hoc analysis of data collected during the Halt Progression of Polycystic Kidney Disease (HALT-PKD) trials. Setting & Participants: 494 HALT-PKD Study A participants (younger; preserved eGFR) and 435 Study B participants (older; reduced eGFR) who had more than 3 years of follow-up and 7 or more eGFR assessments. Measurements: Longitudinal eGFR assessments using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine equation. Predictors: Demographic, clinical, laboratory, and imaging features of participants. Outcomes: Probability of linear and nonlinear decline patterns or of stable eGFR calculated for each participant from a Bayesian model of individual eGFR trajectories. Results: Most (62.5% in Study A and 81% in Study B) participants had a linear decline in eGFR during up to 8 years of follow-up. A proportion (22% in Study A and 13% in Study B) of progressors had a nonlinear pattern. 15.5% of participants in Study A and 6% in Study B had a prolonged (≥4.5 years) period of stable eGFRs. These individuals (Study A) had significantly smaller total kidney volumes, higher renal blood flows, lower urinary albumin excretion, and lower body mass index at baseline and study end. In Study B, participants with reduced but stable eGFRs were older than the progressors. Two-thirds of nonprogressors in both studies had PKD1 mutations, with enrichment for weak nontruncating mutations. Limitations: Relatively short follow-up of a clinical trial population. Conclusions: Although many individuals with ADPKD have a linear decline in eGFR, prolonged intervals of stable GFRs occur in a substantial fraction. Lower body mass index was associated with more stable kidney function in early ADPKD.
AB - Background: Previous clinical studies of autosomal dominant polycystic kidney disease (ADPKD) reported that loss of kidney function usually follows a steep and relentless course. A detailed examination of individual patterns of decline in estimated glomerular filtration rate (eGFR) has not been performed. Study Design: Longitudinal post hoc analysis of data collected during the Halt Progression of Polycystic Kidney Disease (HALT-PKD) trials. Setting & Participants: 494 HALT-PKD Study A participants (younger; preserved eGFR) and 435 Study B participants (older; reduced eGFR) who had more than 3 years of follow-up and 7 or more eGFR assessments. Measurements: Longitudinal eGFR assessments using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine equation. Predictors: Demographic, clinical, laboratory, and imaging features of participants. Outcomes: Probability of linear and nonlinear decline patterns or of stable eGFR calculated for each participant from a Bayesian model of individual eGFR trajectories. Results: Most (62.5% in Study A and 81% in Study B) participants had a linear decline in eGFR during up to 8 years of follow-up. A proportion (22% in Study A and 13% in Study B) of progressors had a nonlinear pattern. 15.5% of participants in Study A and 6% in Study B had a prolonged (≥4.5 years) period of stable eGFRs. These individuals (Study A) had significantly smaller total kidney volumes, higher renal blood flows, lower urinary albumin excretion, and lower body mass index at baseline and study end. In Study B, participants with reduced but stable eGFRs were older than the progressors. Two-thirds of nonprogressors in both studies had PKD1 mutations, with enrichment for weak nontruncating mutations. Limitations: Relatively short follow-up of a clinical trial population. Conclusions: Although many individuals with ADPKD have a linear decline in eGFR, prolonged intervals of stable GFRs occur in a substantial fraction. Lower body mass index was associated with more stable kidney function in early ADPKD.
KW - Autosomal dominant polycystic kidney disease (ADPKD)
KW - Bayesian models
KW - eGFR slope
KW - eGFR trajectory
KW - end-stage renal disease (ESRD)
KW - estimated glomerular filtration rate (eGFR)
KW - kidney disease progression
KW - mutation analysis
KW - total kidney volume
UR - http://www.scopus.com/inward/record.url?scp=85039853711&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2017.10.023
DO - 10.1053/j.ajkd.2017.10.023
M3 - Article
C2 - 29306517
AN - SCOPUS:85039853711
SN - 0272-6386
VL - 71
SP - 666
EP - 676
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 5
ER -